Skip to main content
AKTS
NASDAQ Life Sciences

Aktis Oncology 获得 FDA 批准启动 1B 期肿瘤治疗试验

feedReported by Dow Jones Newswires
Sentiment info
Positive
Importance info
8
Price
$16.54
Mkt Cap
$912.508M
52W Low
$14.72
52W High
$24.5
Market data snapshot near publication time

summarizeSummary

Aktis Oncology 已获得 FDA 批准其新药调查申请（IND）用于 AKY-2519，一种针对多种肿瘤中表达的基因的迷你蛋白放射性联接物。该批准允许公司继续进行 1B 期临床试验，预计将于 2026 年中期开始。这种监管进展是公司管道的一个重要积极步骤，降低了其开发潜在新癌症治疗的途径风险。公司还报告了 2025 年扩大的 6370 万美元亏损，由于研发费用增加，但强调了 2.268 亿美元的强劲现金储备，由 1 月份 IPO 的 3.353 亿美元补充，预计将资助公司运营至 2029 年。这一强劲的财务跑道为公司在获得积极监管新闻后继续药物开发提供了稳定性。

在该公告发布时，AKTS的交易价格为$16.54，交易所为NASDAQ，所属行业为Life Sciences，市值约为$9.1亿。 52周交易区间为$14.72至$24.50。 这则新闻被评估为积极市场情绪，重要性评分为8/10。 来源：Dow Jones Newswires。

show_chartPrice Chart

Share this article

Copied!

feed AKTS - Latest Insights

AKTS
Apr 16, 2026, 4:01 PM EDT
Filing Type: 8-K
Importance Score:
7
Aktis Oncology Appoints Industry R&D Veteran Glenn Gormley to Board, Establishes Science & Tech Committee
Sentiment: Positive
View Wiseek Article
AKTS
Mar 30, 2026, 5:29 PM EDT
Filing Type: 10-K
Importance Score:
8
Aktis Oncology Reports Key Pipeline Progress: AKY-2519 IND Cleared, AKY-1189 Granted Fast Track, Strong Cash Runway into 2029
Sentiment: Positive
View Wiseek Article
AKTS
Mar 30, 2026, 4:45 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
Aktis Oncology Gains FDA Clearance for Phase 1B Tumor Treatment Trial
Sentiment: Positive
View Wiseek Article
AKTS
Jan 20, 2026, 5:44 PM EST
Filing Type: SCHEDULE 13D
Importance Score:
8
MPM Entities and Affiliates Disclose 19.3% Stake in Aktis Oncology Following IPO
Sentiment: Positive
View Wiseek Article
AKTS
Jan 20, 2026, 2:01 PM EST
Filing Type: SCHEDULE 13D
Importance Score:
8
EcoR1 Capital and Director Oleg Nodelman Disclose 9.1% Stake in Aktis Oncology
Sentiment: Positive
View Wiseek Article
AKTS
Jan 15, 2026, 6:02 AM EST
Filing Type: SCHEDULE 13D
Importance Score:
9
Eli Lilly Acquires 11.9% Stake in Aktis Oncology for $112M in IPO and Pre-IPO Investments
Sentiment: Positive
View Wiseek Article
AKTS
Jan 14, 2026, 6:20 PM EST
Filing Type: 4
Importance Score:
8
Director and 10% Owner Todd Foley Acquires $87.5M in Aktis Oncology Stock, Including $4.2M Open Market Purchase
Sentiment: Positive
View Wiseek Article
AKTS
Jan 14, 2026, 6:19 PM EST
Filing Type: 4
Importance Score:
7
Major Investor Luke Evnin and MPM BioVentures Boost Aktis Oncology Stake with $20M Open Market Buy and Preferred Stock Conversions
Sentiment: Positive
View Wiseek Article
AKTS
Jan 14, 2026, 6:17 PM EST
Filing Type: 4
Importance Score:
7
10% Owner Ansbert Gadicke and Affiliates Increase Stake in Aktis Oncology by Over $203 Million
Sentiment: Positive
View Wiseek Article
AKTS
Jan 14, 2026, 4:58 PM EST
Filing Type: SCHEDULE 13D
Importance Score:
8
Vida Ventures and Director Helen Kim Disclose 10.9% Stake in Aktis Oncology Following IPO
Sentiment: Positive
View Wiseek Article